Subscribe to Market Briefs for FREE and get daily investor updates: FREE Passive Income PDF Download it here: Recommended: ...

Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral ant ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Video has captured the moment suspect Fale Pea, who has an extensive criminal history, brutally attacked a random 75-year-old woman in Seattle, Washington, on Dec. 5. (King County Prosecuting Attorney ...

Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...

Internet users can’t cope with the adorable moment a deaf and blind dog tried to greet his owner—but encountered a little trouble finding him. The video was shared on the canine’s dedicated TikTok ...

Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for ...

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. As physicians who specialize in emergency medicine and ...

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...

A systematic review and meta-analysis of 15 studies found that ketogenic diets were associated with short-term reductions in ...

MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase ...